Physician profile
Rachel Lin
NPI 1770901282
$865.08
in general payments reported to CMS, 2019-2025
3 companies · $224 in 2025
The $224 reported for 2025 was more than what 78% of Dentist providers received nationally (typical 2025 total: $70.27).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2021: $56.81 · 2023: $87.40 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224 · Education: $87.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $224.45 |
| Education | $87.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $496.42 | 2019 | |
| Zimvie INC. | $224.45 | 2025 | |
| Colgate Oral Pharmaceuticals, INC. | $144.21 | 2021-2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.